Mark Jeffrey DeLong insider trades: Apellis Pharmaceuticals (APLS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
27 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | APLS | ↓ Sell | 368 | $22.15 | $8K | Direct | Feb 13, 2026 (2d) |
| Jan 22, 2026 | APLS | ↓ Sell | 3,371 | $21.77 | $73K | Direct | Jan 23, 2026 (1d) |
| Jan 20, 2026 | APLS | ↓ Sell | 1,334 | $19.79 | $26K | Direct | Jan 21, 2026 (1d) |
| Jan 13, 2026 | APLS | ↓ Sell | 1,780 | $22.19 | $39K | Direct | Jan 15, 2026 (2d) |
| Feb 11, 2025 | APLS | ↓ Sell | 363 | $28.54 | $10K | Direct | Feb 12, 2025 (1d) |
| Jan 29, 2025 | APLS | ↓ Sell | 365 | $29.52 | $11K | Direct | Jan 30, 2025 (1d) |
| Jan 22, 2025 | APLS | ↓ Sell | 1,396 | $30.43 | $42K | Direct | Jan 23, 2025 (1d) |
| Jan 17, 2025 | APLS | ↓ Sell | 1,235 | $29.96 | $37K | Direct | Jan 21, 2025 (4d) |
| Jan 13, 2025 | APLS | ↓ Sell | 1,599 | $28.70 | $46K | Direct | Jan 14, 2025 (1d) |
| Mar 18, 2024 | APLS | ↓ Sell | 9,913 | $56.90 | $564K | Direct | Mar 19, 2024 (1d) |
| Feb 12, 2024 | APLS | ↓ Sell | 597 | $67.77 | $40K | Direct | Feb 13, 2024 (1d) |
| Jan 29, 2024 | APLS | ↓ Sell | 367 | $64.14 | $24K | Direct | Jan 31, 2024 (2d) |
| Jan 22, 2024 | APLS | ↓ Sell | 1,384 | $65.00 | $90K | Direct | Jan 23, 2024 (1d) |
| Jan 16, 2024 | APLS | ↓ Sell | 1,631 | $66.81 | $109K | Direct | Jan 17, 2024 (1d) |
| Oct 23, 2023 | APLS | ↓ Sell | 131 | $46.04 | $6K | Direct | Oct 24, 2023 (1d) |
| Aug 17, 2022 | APLS | ↓ Sell | 5,000 | $69.50 | $348K | Direct | Aug 18, 2022 (1d) |
| Aug 11, 2022 | APLS | ↓ Sell | 5,000 | $67.00 | $335K | Direct | Aug 12, 2022 (1d) |
| Aug 8, 2022 | APLS | ↓ Sell | 5,000 | $64.50 | $323K | Direct | Aug 9, 2022 (1d) |
| Aug 4, 2022 | APLS | ↓ Sell | 10,000 | $60.75 | $608K | Direct | Aug 8, 2022 (4d) |
| Jul 27, 2022 | APLS | ↓ Sell | 5,000 | $57.00 | $285K | Direct | Jul 28, 2022 (1d) |
| Jul 19, 2022 | APLS | ↓ Sell | 5,000 | $56.42 | $282K | Direct | Jul 21, 2022 (2d) |
| Jun 16, 2022 | APLS | ↓ Sell | 10,000 | $41.78 | $418K | Direct | Jun 21, 2022 (5d) |
| Apr 20, 2022 | APLS | ↓ Sell | 7,000 | $52.53 | $368K | Direct | Apr 22, 2022 (2d) |
| Jul 21, 2021 | APLS | ↓ Sell | 1,000 | $65.00 | $65K | Direct | Jul 22, 2021 (1d) |
| Jul 15, 2021 | APLS | ↓ Sell | 1,000 | $62.30 | $62K | Direct | Jul 16, 2021 (1d) |
| Jun 15, 2021 | APLS | ↓ Sell | 4,000 | $64.96 | $260K | Direct | Jun 16, 2021 (1d) |
| May 18, 2021 | APLS | ↓ Sell | 2,000 | $55.00 | $110K | Direct | May 19, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APLS insiders
Open-market trades in the last 12 months
About Mark Jeffrey DeLong's insider trades
Mark Jeffrey DeLong is Chief Business & Strat Officer at Apellis Pharmaceuticals (APLS). Since May 18, 2021, Mark has reported no open-market purchases and 27 sales worth $4.6M on SEC Form 4. In the last 12 months: 4 sales ($147K).
Their filings also include option exercises (13 filings), grants and awards (10 filings), shares withheld for taxes (7 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.